Maternal and health worker preferences for paediatric antiretroviral formulations in neonates exposed to HIV
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Mothers and healthcare providers prefer novel dolutegravir (DTG) oral films for infant antiretroviral therapy over existing syrups. These new formulations offer easier administration and accurate dosing for neonates born to mothers living with HIV.
Area Of Science
- Pediatric infectious diseases
- HIV/AIDS treatment
- Pharmaceutical formulation development
Background
- Oral liquid zidovudine (ZDV) and nevirapine (NVP) are standard antiretrovirals (ARVs) for neonates exposed to HIV.
- Current formulations present challenges such as poor palatability, short shelf-life, frequent dosing, and supply issues.
Purpose Of The Study
- To assess caregiver and healthcare provider preferences for novel infant antiretroviral (ARV) formulations.
- To inform the development of acceptable and usable ARV alternatives for neonates.
Main Methods
- A preference ranking exercise was conducted within the PETITE-DTG trial (NCT05590325) in South Africa.
- Participants (28 mothers, 6 health workers) ranked six ARV formulations: ZDV syrup, NVP syrup, dolutegravir (DTG) dispersible tablet (DTG-DT), DTG oral dispersible film (DTG-film), a long-acting injectable, and a transdermal patch.
Main Results
- Both mothers and health workers strongly preferred the DTG oral dispersible film, citing ease of administration, accurate dosing, and discretion.
- Long-acting injectables were the second preference, valued for convenience despite potential discomfort.
- Existing ZDV and NVP syrups, along with the DTG dispersible tablet, were ranked lower due to preparation difficulties and spillage risks.
- Transdermal patches received the lowest preference due to concerns about infant comfort, water exposure, and efficacy.
Conclusions
- Innovative ARV formulations, particularly the DTG oral dispersible film, are highly favored for neonatal HIV treatment.
- Usability, ease of administration, and reduced dosing frequency are key factors driving preference for new ARV options.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...